Evidence map›Paper›PMID 41167457›Full record

ReviewProgress in retinal and eye research2025

Imaging of the retinal hypoxia: A journey from oxygen microelectrode to the first hypoxia imaging in the living retina.

Md Imam Uddin

Abstract readReview
In one paragraph

Review in Progress in retinal and eye research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Md Imam UddinDepartment of Ophthalmology and Visual Sciences, Vanderbilt University School of Medicine, Nashville, TN, 37232, USA; Department of Biomedical Engineering, Vanderbilt University School of Engineering, Nashville, TN, 37235, USA. Electronic address: md.i.uddin@vumc.org.

Funding

In Vivo Molecular Imaging of the RetinaR01EY023397 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI PENN, JOHN S., UDDIN, MD IMAM · 2013 to 2022
$3.6M
In Vivo Molecular Imaging of Vascular Disease of the RetinaR01EY029693 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI UDDIN, MD IMAM · 2019 to 2023
$2.1M
NEI NIH HHS R01 EY023397NEI NIH HHS R01 EY029693
6 · The paper itself

Abstract

Oxygen is the major element for metabolism in the retina. Reduced oxygen supply causes significant changes in cellular metabolism and gene expression in the retina initiating inflammasome activation, apoptosis of retinal cells, mitochondrial damage, oxidative stress and neurodegeneration. Physiologically, retinal hypoxia plays important role regulating vasculogenesis during our development in early life. Retinal hypoxia also plays key regulatory roles during the onset and progression of many retinopathy conditions including neovascularization at later stages of our life. Though the exact mechanism of neovascularization is still largely unknown, hypoxia may contribute to the over expression of vascular endothelial growth factor (VEGF), and VEGF is a known inducer of neovascularization. Thus, molecular imaging of retinal hypoxia could be an important diagnostic tool assessing the risk of retinopathy, its progression, and response to therapy. Imaging retinal hypoxia is also an important diagnostic tool assessing the risk of inflammasome activation, mitochondrial damage, oxidative stress and apoptosis of retinal cells at molecular levels. This review will provide an overview of technologies to detect retinal hypoxia in the living retinal tissues before the onset of tissue damage. This review will also discuss the design and development of HYPOX-4, a highly sensitive molecular imaging probe capable of detecting retinal hypoxia in the living retina before the onset of neovascularization. The author will further discuss a quantitative method to assess HYPOX-4 fluorescence intensity measurement by computational methods, correlating with levels of retinal hypoxia and create a predictive biomarker for retinal neovascularization. An overview of the technology development will also include Dr. Linsenmeier's early development of microelectrode for our fundamental understanding of retinal tissue oxygenation using an invasive measurement technique. An overview of the other emerging technologies, including retinal oximetry, phosphorescence lifetime imaging and photoacoustic imaging will be discussed.

Indexed as

HypoxiaMolecular ImagingOxygenRetinaRetinal DiseasesAnimalsHumansOxygenFluorescence imagingHYPOX-4Molecular imagingOptical imagingRetinal hypoxia

Identifiers

PMID41167457
PMCPMC13283042

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.